NovaBay Pharmaceuticals to Present at 29th Annual ROTH Conference

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that Chairman, President and CEO Mark M. Sieczkarek is scheduled to present a corporate overview at the 29th Annual ROTH Conference on Tuesday, March 14, 2017, at 3:30 p.m. Pacific time (6:30 p.m. Eastern time). The conference is being held at The Ritz-Carlton, Laguna Niguel in Dana Point, Calif.

A live webcast and replay will be available on the Investors section of the Company's website at http://novabay.com/investors/events.

About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®Avenova is formulated with Neutrox®, which is cleared by the U.S. Food and Drug Administration (FDA) as a 510(k) medical device. Neutrox is NovaBay’s commercial name for its proprietary pure hypochlorous acid. Data from a multicenter clinical study show that Avenova reduced bacterial load, the underlying cause of blepharitis, on ocular skin surface by more than 90%. Laboratory tests show that hypochlorous acid has potent antimicrobial activity in solution yet is non-toxic to mammalian cells and also neutralizes bacterial toxins. Avenova is marketed to optometrists and ophthalmologists throughout the U.S. by NovaBay’s direct salesforce. It is accessible from more than 90% of retail pharmacies in the U.S. through agreements with McKesson Corporation, Cardinal Health and AmerisourceBergen.

Stay informed on NovaBay's progress:Download our Mobile InvestorApp from the Apple Store or Google PlayLike us on FacebookFollow us on TwitterConnect with NovaBay on LinkedInJoin us on Google+Visit NovaBay's Website

View source version on businesswire.com: http://www.businesswire.com/news/home/20170307005405/en/

NovaBay ContactsFor NovaBay Avenova purchasing information, please contact:Email usCall us: 1-800-890-0329www.Avenova.comorFrom the CompanyThomas J. Paulson, 510-899-8809Chief Financial OfficerContact TomorInvestor Contact:LHAJody Cain, [e-mail]